Eintrag weiter verarbeiten
Modern Strategies for Hairy Cell Leukemia
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Journal of Clinical Oncology, 29, 2011, 5, S. 583-590 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Grever, Michael R. Lozanski, Gerard Grever, Michael R. Lozanski, Gerard |
|---|---|
| author |
Grever, Michael R. Lozanski, Gerard |
| spellingShingle |
Grever, Michael R. Lozanski, Gerard Journal of Clinical Oncology Modern Strategies for Hairy Cell Leukemia Cancer Research Oncology |
| author_sort |
grever, michael r. |
| spelling |
Grever, Michael R. Lozanski, Gerard 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.31.7016 <jats:p> Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial major therapeutic advances in the management of this disease in 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history of this rare disease by achieving a high rate of complete and durable remissions. The disease-free survival after effective therapy has not reached a plateau, suggesting control but not cure of the disease. Identification of minimal residual disease in patients achieving a complete hematologic remission provides insight into the potential source for predicting eventual relapse. Modern strategies of targeted therapies directed against immunophenotypic markers on the leukemic cells provide hope that improved long-term control of the disease is possible. Combined chemoimmunotherapy may hold the highest promise for disease eradication, but the optimal strategy for using this approach is under active investigation. Despite the perception by hematologists that this disease has already been conquered, there are critically important unanswered questions that remain. Investigation of the bone marrow microenvironment and its impact on minimal residual disease may ultimately prevent relapse. Consideration of the median age of patients at diagnosis combined with a substantial relapse rate mandates continued pursuit of improved therapy. The ultimate goal will be to achieve cure rather than simple control of the disease. </jats:p> Modern Strategies for Hairy Cell Leukemia Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2010.31.7016 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMS43MDE2 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMS43MDE2 |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 |
| imprint |
American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2011 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
grever2011modernstrategiesforhairycellleukemia |
| publishDateSort |
2011 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Modern Strategies for Hairy Cell Leukemia |
| title_unstemmed |
Modern Strategies for Hairy Cell Leukemia |
| title_full |
Modern Strategies for Hairy Cell Leukemia |
| title_fullStr |
Modern Strategies for Hairy Cell Leukemia |
| title_full_unstemmed |
Modern Strategies for Hairy Cell Leukemia |
| title_short |
Modern Strategies for Hairy Cell Leukemia |
| title_sort |
modern strategies for hairy cell leukemia |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2010.31.7016 |
| publishDate |
2011 |
| physical |
583-590 |
| description |
<jats:p> Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial major therapeutic advances in the management of this disease in 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history of this rare disease by achieving a high rate of complete and durable remissions. The disease-free survival after effective therapy has not reached a plateau, suggesting control but not cure of the disease. Identification of minimal residual disease in patients achieving a complete hematologic remission provides insight into the potential source for predicting eventual relapse. Modern strategies of targeted therapies directed against immunophenotypic markers on the leukemic cells provide hope that improved long-term control of the disease is possible. Combined chemoimmunotherapy may hold the highest promise for disease eradication, but the optimal strategy for using this approach is under active investigation. Despite the perception by hematologists that this disease has already been conquered, there are critically important unanswered questions that remain. Investigation of the bone marrow microenvironment and its impact on minimal residual disease may ultimately prevent relapse. Consideration of the median age of patients at diagnosis combined with a substantial relapse rate mandates continued pursuit of improved therapy. The ultimate goal will be to achieve cure rather than simple control of the disease. </jats:p> |
| container_issue |
5 |
| container_start_page |
583 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
29 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334813216112646 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:34:35.347Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Modern+Strategies+for+Hairy+Cell+Leukemia&rft.date=2011-02-10&genre=article&issn=1527-7755&volume=29&issue=5&spage=583&epage=590&pages=583-590&jtitle=Journal+of+Clinical+Oncology&atitle=Modern+Strategies+for+Hairy+Cell+Leukemia&aulast=Lozanski&aufirst=Gerard&rft_id=info%3Adoi%2F10.1200%2Fjco.2010.31.7016&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334813216112646 |
| author | Grever, Michael R., Lozanski, Gerard |
| author_facet | Grever, Michael R., Lozanski, Gerard, Grever, Michael R., Lozanski, Gerard |
| author_sort | grever, michael r. |
| container_issue | 5 |
| container_start_page | 583 |
| container_title | Journal of Clinical Oncology |
| container_volume | 29 |
| description | <jats:p> Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial major therapeutic advances in the management of this disease in 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history of this rare disease by achieving a high rate of complete and durable remissions. The disease-free survival after effective therapy has not reached a plateau, suggesting control but not cure of the disease. Identification of minimal residual disease in patients achieving a complete hematologic remission provides insight into the potential source for predicting eventual relapse. Modern strategies of targeted therapies directed against immunophenotypic markers on the leukemic cells provide hope that improved long-term control of the disease is possible. Combined chemoimmunotherapy may hold the highest promise for disease eradication, but the optimal strategy for using this approach is under active investigation. Despite the perception by hematologists that this disease has already been conquered, there are critically important unanswered questions that remain. Investigation of the bone marrow microenvironment and its impact on minimal residual disease may ultimately prevent relapse. Consideration of the median age of patients at diagnosis combined with a substantial relapse rate mandates continued pursuit of improved therapy. The ultimate goal will be to achieve cure rather than simple control of the disease. </jats:p> |
| doi_str_mv | 10.1200/jco.2010.31.7016 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4zMS43MDE2 |
| imprint | American Society of Clinical Oncology (ASCO), 2011 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2011 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T14:34:35.347Z |
| match_str | grever2011modernstrategiesforhairycellleukemia |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 583-590 |
| publishDate | 2011 |
| publishDateSort | 2011 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Grever, Michael R. Lozanski, Gerard 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.31.7016 <jats:p> Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial major therapeutic advances in the management of this disease in 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed the natural history of this rare disease by achieving a high rate of complete and durable remissions. The disease-free survival after effective therapy has not reached a plateau, suggesting control but not cure of the disease. Identification of minimal residual disease in patients achieving a complete hematologic remission provides insight into the potential source for predicting eventual relapse. Modern strategies of targeted therapies directed against immunophenotypic markers on the leukemic cells provide hope that improved long-term control of the disease is possible. Combined chemoimmunotherapy may hold the highest promise for disease eradication, but the optimal strategy for using this approach is under active investigation. Despite the perception by hematologists that this disease has already been conquered, there are critically important unanswered questions that remain. Investigation of the bone marrow microenvironment and its impact on minimal residual disease may ultimately prevent relapse. Consideration of the median age of patients at diagnosis combined with a substantial relapse rate mandates continued pursuit of improved therapy. The ultimate goal will be to achieve cure rather than simple control of the disease. </jats:p> Modern Strategies for Hairy Cell Leukemia Journal of Clinical Oncology |
| spellingShingle | Grever, Michael R., Lozanski, Gerard, Journal of Clinical Oncology, Modern Strategies for Hairy Cell Leukemia, Cancer Research, Oncology |
| title | Modern Strategies for Hairy Cell Leukemia |
| title_full | Modern Strategies for Hairy Cell Leukemia |
| title_fullStr | Modern Strategies for Hairy Cell Leukemia |
| title_full_unstemmed | Modern Strategies for Hairy Cell Leukemia |
| title_short | Modern Strategies for Hairy Cell Leukemia |
| title_sort | modern strategies for hairy cell leukemia |
| title_unstemmed | Modern Strategies for Hairy Cell Leukemia |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2010.31.7016 |